Sarepta Therapeutics, Inc.
215 First Street
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD) and CNS. The Company now has 23 programs in development across several therapeutic modalities, including RNA, gene therapy and gene editing.
Sarepta is writing a new play book, one that has the potential to define rare disease drug development.
- We place the patient front and center to everything we do and every decision we make.
- We are a science-driven organization.
- We work with a bias to action.
- We attract employees who want to make a difference and aren't afraid of upsetting the “norm” - we like disrupters.
- We invest heavily in R&D and are pursuing a model where the pathway is defined and the science compelling.
Sarepta's largest employee population is based in Massachusetts with headquarters in Cambridge and a manufacturing and laboratory facility in Andover, with plans to build a gene therapy Research Center of Excellence in Columbus, Ohio. The Company is also establishing its global presence with new offices in Brazil, Ireland, UK, Germany, France, Italy, and the Nordics, with European headquarters in Zug, Switzerland.
Corporate Mission Statement:
Leading the field of precision medicine to forever change the course of rare disease so patients can dream big, live fully and journey far.
Stock Symbol: SRPT
Stock Exchange: NASDAQ
Check out careers with Sarepta here.
World Duchenne Awareness Day (WDAD) at Sarepta Therapeutics
Sarepta raises awareness for Duchenne muscular dystrophy (DMD) on World Duchenne Awareness Day - September 2018
600 articles with Sarepta Therapeutics, Inc.
AcelRx is seeking $40 million to support the launch of Dsuvia and Sarepta eyes $500 million to support clinical research.
Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Beta-sarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E
First-in-human trial of MYO-101 based on promising pre-clinical results offering the first corrective approach for LGMD2E
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
The American University Washington College of Law and the Food and Drug Law Institute hosted a conference late last week. One of the highlights was a plenary session that featured former commissioners of the U.S. Food and Drug Administration (FDA).
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Expands Sarepta’s portfolio to as many as 14 gene therapy programs
Sarepta Therapeutics’ experimental gene-therapy treatment for Duchenne muscular dystrophy (DMD) is showing some early signs of promise. Patients who received the therapy are showing increasing signs of a muscle protein that had been missing, the company said.
Sarepta Therapeutics Announces that at the 23rd International Congress of the World Muscle Society, Jerry Mendell, M.D., Presented Positive Updated Results from the Four Children Dosed in the Gene Therapy Micro-dystrophin Trial
Biopsy of fourth patient showed robust micro-dystrophin expression as measured by Western blot and immunohistochemistry
Sarepta Announces Clinical Hold Lifted for its Duchenne Muscular Dystrophy Micro-dystrophin Gene ...
9/24/2018Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that the Food and Drug Administration (FDA) has lifted the clinical hold for the Company's Duchenne...
In September 2016, the U.S. FDA approved Sarepta Therapeutics’ eteplirsen, now marketed as Exondys 51, for Duchenne muscular dystrophy (DMD). And now, two years later, the European Medicines Agency (EMA) has rejected Sarepta’s application for Exondys 51.
Researchers at the University of Texas Southwestern Medical Center used CRISPR gene editing to treat Duchenne muscular dystrophy (DMD) in dogs. Their work was published in the journal Science.
Pfizer terminated two clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).
8/30/2018Recently, Milton Packer, a renowned cardiologist at Baylor Scott & White Health, wrote a criticism of the Orphan Drug Act and the resulting problems caused by the biopharma industry. John LaMattina, formerly president of Pfizer Global Research and Development and a current senior partner at PureT...
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Cambridge, Mass.-based Sarepta Therapeutics expanded its gene therapy pipeline up to 11 in an equity deal with Lacerta Therapeutics. Investing $30 million into Alachua, Florida-based Lacerta Therapeutics, Sarepta gained access to the company’s AAV-based CNS-targeted gene therapies.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or ...
Dedicated Online Platform DuchenneXchange.org Launches to Unite, Support and Educate Duchenne Community
The Duchenne muscular dystrophy (DMD) community now has a dedicated online platform where they can connect and share knowledge - DuchenneXchange (DuchenneXchange.org)
The FDA notified Sarepta Therapeutics that its Phase I/IIa Micro-Dystrophin Gene Therapy Trial for Duchenne muscular dystrophy (DMD) has been placed on a clinical hold because of contamination of its therapeutic.
Sarepta Therapeutics, Inc. and CureDuchenne to Host Webinar on Duchenne Muscular Dystrophy Programs Utilizing Sarepta’s RNA-Targeted Technology Platforms
Sarepta Therapeutics, Inc. and non-profit CureDuchenne announced today they have partnered to host a free webinar to provide Duchenne muscular dystrophy patients, caregivers and advocates a comprehensive review of Sarepta’s RNA-targeted technology platforms (PMO and PPMO).
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
Miracles, it seems, have a high price tag. At least, if those miracles are miracle drugs. There’s no doubt that trends in gene therapy and immuno-oncology are producing drugs that are as close to miraculous as we’re likely to get, doing a great job, generally, in beating back diseases that to thi...